Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nascent Biotech Inc
(OP:
NBIO
)
0.0008
UNCHANGED
Streaming Delayed Price
Updated: 1:45 PM EDT, Oct 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0008
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0008
Today's Range
0.0008 - 0.0008
52wk Range
0.0001 - 0.0952
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing
January 21, 2025
From
Nascent Biotech Inc
Via
GlobeNewswire
Nascent Biotech Presents at the July Emerging Growth Conference
July 30, 2024
Via
ACCESSWIRE
Performance
YTD
-98.4%
-98.4%
1 Month
-90.6%
-90.6%
3 Month
-27.3%
-27.3%
6 Month
-69.2%
-69.2%
1 Year
-98.9%
-98.9%
More News
Read More
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
April 16, 2024
Via
ACCESSWIRE
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
March 19, 2024
Via
ACCESSWIRE
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
January 09, 2024
Via
ACCESSWIRE
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
February 06, 2024
Via
ACCESSWIRE
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
December 19, 2023
Via
ACCESSWIRE
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
November 29, 2023
Via
ACCESSWIRE
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
August 22, 2023
Via
ACCESSWIRE
Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
June 07, 2023
Via
ACCESSWIRE
Nascent Biotech Regains Worldwide Rights for Pritumumab
May 26, 2023
Via
ACCESSWIRE
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
May 09, 2023
Via
ACCESSWIRE
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
April 18, 2023
Via
ACCESSWIRE
Nascent Announces the Completion of Its Phase1 Clinical Trials
February 28, 2023
Via
ACCESSWIRE
Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
January 25, 2023
Via
ACCESSWIRE
Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
January 10, 2023
Via
ACCESSWIRE
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
December 20, 2022
Via
ACCESSWIRE
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
November 01, 2022
Via
ACCESSWIRE
Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
October 04, 2022
Via
ACCESSWIRE
Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
September 13, 2022
Via
ACCESSWIRE
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
July 19, 2022
Via
ACCESSWIRE
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
July 19, 2022
From
Nascent Biotech Inc.
Via
AccessWire
Topics
Intellectual Property
Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
June 07, 2022
From
Nascent Biotech Inc.
Via
AccessWire
Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
May 04, 2022
From
Nascent Biotech Inc.
Via
AccessWire
Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
April 12, 2022
From
Nascent Biotech Inc.
Via
AccessWire
Frequently Asked Questions
Is Nascent Biotech Inc publicly traded?
Yes, Nascent Biotech Inc is publicly traded.
What exchange does Nascent Biotech Inc trade on?
Nascent Biotech Inc trades on the OTC Traded
What is the ticker symbol for Nascent Biotech Inc?
The ticker symbol for Nascent Biotech Inc is NBIO on the OTC Traded
What is the current price of Nascent Biotech Inc?
The current price of Nascent Biotech Inc is 0.0008
When was Nascent Biotech Inc last traded?
The last trade of Nascent Biotech Inc was at 10/15/25 01:45 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.